Identifying and predicting Parkinson’s disease subtypes through trajectory clustering via bipartite networks

Chronic medical conditions show substantial heterogeneity in their clinical features and progression. We develop the novel data-driven, network-based Trajectory Profile Clustering (TPC) algorithm for 1) identification of disease subtypes and 2) early prediction of subtype/disease progression patterns. TPC is an easily generalizable method that identifies subtypes by clustering patients with similar disease trajectory profiles, based not only on Parkinson’s Disease (PD) variable severity, but also on their complex patterns of evolution. TPC is derived from bipartite networks that connect patients to disease variables. Applying our TPC algorithm to a PD clinical dataset, we identify 3 distinct subtypes/patient clusters, each with a characteristic progression profile. We show that TPC predicts the patient’s disease subtype 4 years in advance with 72% accuracy for a longitudinal test cohort. Furthermore, we demonstrate that other types of data such as genetic data can be integrated seamlessly in the TPC algorithm. In summary, using PD as an example, we present an effective method for subtype identification in multidimensional longitudinal datasets, and early prediction of subtypes in individual patients.

[1]  M. DePamphilis,et al.  HUMAN DISEASE , 1957, The Ulster Medical Journal.

[2]  Jean-Loup Guillaume,et al.  Fast unfolding of communities in large networks , 2008, 0803.0476.

[3]  M E J Newman,et al.  Finding and evaluating community structure in networks. , 2003, Physical review. E, Statistical, nonlinear, and soft matter physics.

[4]  Kang K. L. Liu,et al.  Focus on the emerging new fields of network physiology and network medicine , 2016, New journal of physics.

[5]  N. Jetté,et al.  The prevalence of Parkinson's disease: A systematic review and meta‐analysis , 2014, Movement disorders : official journal of the Movement Disorder Society.

[6]  A. Dagher,et al.  Clinical criteria for subtyping Parkinson’s disease: biomarkers and longitudinal progression , 2017, Brain : a journal of neurology.

[7]  Sonja W. Scholz,et al.  Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies , 2019, The Lancet Neurology.

[8]  Mason A. Porter,et al.  Multilayer networks , 2013, J. Complex Networks.

[9]  Stephanie A. Santorico,et al.  Cluster analysis in the COPDGene study identifies subtypes of smokers with distinct patterns of airway disease and emphysema , 2014, Thorax.

[10]  A. Barabasi,et al.  The human disease network , 2007, Proceedings of the National Academy of Sciences.

[11]  Joel S. Perlmutter,et al.  Variants in GBA, SNCA, and MAPT influence Parkinson disease risk, age at onset, and progression , 2016, Neurobiology of Aging.

[12]  J. Jankovic,et al.  Parkinson disease subtypes. , 2014, JAMA neurology.

[13]  Jean-François Gagnon,et al.  New Clinical Subtypes of Parkinson Disease and Their Longitudinal Progression: A Prospective Cohort Comparison With Other Phenotypes. , 2015, JAMA neurology.

[14]  R. Barker,et al.  The heterogeneity of idiopathic Parkinson's disease , 2002, Journal of Neurology.

[15]  T. Robbins,et al.  Heterogeneity of Parkinson’s disease in the early clinical stages using a data driven approach , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[16]  Albert-László Barabási,et al.  A Dynamic Network Approach for the Study of Human Phenotypes , 2009, PLoS Comput. Biol..

[17]  R. Barker,et al.  Developing and validating Parkinson’s disease subtypes and their motor and cognitive progression , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.

[18]  A. Barabasi,et al.  Network medicine : a network-based approach to human disease , 2010 .

[19]  L. Shulman,et al.  Clinical subtypes and genetic heterogeneity: of lumping and splitting in Parkinson disease. , 2016, Current opinion in neurology.

[20]  Jose A. Santiago,et al.  A network approach to clinical intervention in neurodegenerative diseases. , 2014, Trends in molecular medicine.

[21]  Houeto Jean-Luc [Parkinson's disease]. , 2022, La Revue du praticien.

[22]  S. Fereshtehnejad,et al.  Subtypes of Parkinson’s Disease: What Do They Tell Us About Disease Progression? , 2017, Current Neurology and Neuroscience Reports.

[23]  A. Rajput,et al.  Baseline motor findings and Parkinson disease prognostic subtypes , 2017, Neurology.

[24]  A. Lang,et al.  Parkinson's disease subtypes: lost in translation? , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[25]  J. Loscalzo,et al.  The Emerging Paradigm of Network Medicine in the Study of Human Disease , 2012, Circulation research.

[26]  L. Wilkins Genetic risk of Parkinson disease and progression: An analysis of 13 longitudinal cohorts , 2019, Neurology: Genetics.

[27]  Mason A. Porter,et al.  Community Detection in Temporal Multilayer Networks, with an Application to Correlation Networks , 2014, Multiscale Model. Simul..

[28]  T. Montine,et al.  Common variant rs356182 near SNCA defines a Parkinson's disease endophenotype , 2016, Annals of clinical and translational neurology.

[29]  M. Vidal,et al.  Networking metabolites and diseases , 2008, Proceedings of the National Academy of Sciences.

[30]  A. Barabasi,et al.  Controllability analysis of the directed human protein interaction network identifies disease genes and drug targets , 2015, Proceedings of the National Academy of Sciences.

[31]  D. Hernandez,et al.  Genomewide association study of Parkinson's disease clinical biomarkers in 12 longitudinal patients' cohorts , 2019, Movement disorders : official journal of the Movement Disorder Society.

[32]  Jean-Pierre Bouchard,et al.  Replication study of MATR3 in familial and sporadic amyotrophic lateral sclerosis , 2016, Neurobiology of Aging.

[33]  Siddique Latif,et al.  Community detection in networks: A multidisciplinary review , 2018, J. Netw. Comput. Appl..